CASI Pharmaceuticals, Inc 20-F for FY2023
CASI Pharmaceuticals, Inc. (CASIF)
20-F
2024-03-28
For: 2023-12-31
View Original
Added on
April 12, 2026
About this 20-F
CASI Pharmaceuticals, Inc filed this 20-F on March 28, 2024, covering the fiscal year ended December 31, 2023 (FY2023).
Headline figures
Fiscal year ended December 31, 2023, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $33.88M
- down 21.4% from $43.11M a year earlier
- Net loss
- $26.96M
- compared with a net loss of $41.01M a year earlier
- Diluted EPS
- -$2.02
- compared with -$3.01 a year earlier